Ask AI

Capsule Summaries

Share

Program Content

Activities

  • ASCENT03 Safety Analysis
    ASCENT-03: Safety Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Untreated Patients With Advanced TNBC Ineligible for PD-(L)1 Inhibitors
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2025

  • ASCENT07 Primary Results
    ASCENT-07: Primary Results From Sacituzumab Govitecan vs Chemotherapy as First Post-Endocrine Therapy in HR+/HER2- MBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2025

  • PHERGuide
    PHERGuide: A Substudy of Translational Evaluation of ctDNA in Patients With HER2+ EBC Enrolled in PHERGain  
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2025

  • lidERA
    lidERA: Phase III Trial of Adjuvant Giredestrant vs Standard-of-Care Endocrine Therapy for ER+/HER2-Negative Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.